Sort
51,570 grants matching “autoimmune disease”
A Novel Tolerance Therapeutic for Treating Multiple Sclerosis
$1,000,000Neil A Fanger · Virtici, Llc · R44 · FY2017 · AI
Delivery system development for a reservoir targeted Lyme disease vaccine
$1,000,000Linden T Hu · Foodsource Lure Corporation · R42 · FY2012 · AI
Non-Activated Natural Killer Cell Engineering For Enhanced Cytotoxic Potential
$1,000,000Michael Chiu · Kytopen Corp · R44 · FY2025 · AI
Development of a novel accurate therapy for multiple sclerosis
$1,000,000Gaddiel Galarza-Munoz · Autoimmunity Biologic Solutions, Inc. · R42 · FY2022 · AI
Advanced PML antiviral
$1,000,000Milton H. Werner · Inhibikase Therapeutics · R44 · FY2017 · AI
Safe and effective anti CD154 antibodies for therapeutic intervention
$1,000,000Jay L Rothstein · Immunext, Inc. · R44 · FY2015 · AI
Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture
$1,000,000Frederick R Blattner · Scarab Genomics, Llc · R44 · FY2020 · AI
A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis
$1,000,000Gary Fanger · Rise Therapeutics, Llc · R44 · FY2022 · AI
Novel immunotherapy against MOG antibody disease
$1,000,000Weston Daniel · Evoq Therapeutics, Inc. · R44 · FY2024 · TR
Type 1 Diabetes triggers: diet modification in neonates
$1,000,000Diabetes Research Institute · U01 · FY2003 · DK
Diabetes Prediction in Skane(DiPiS)
$1,000,000University Of Washington · U01 · FY2003 · DK
Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening: Aiming toward total in silico design of antibodies
$1,000,000Steven Joseph Darnell · Dnastar, Inc. · R44 · FY2023 · AI
CENTER FOR COMPUTATIONAL BIOLOGY (CCB)(RMI)
$999,999Arthur W Toga · University Of California Los Angeles · U54 · FY2010 · RR
GENETIC DISSECTION OF SLE PATHOGENESIS
$999,998University Of Texas Sw Med Ctr/Dallas · P01 · FY2000 · AI
New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cytometry
$999,998Christopher J Macnevin · Nirvana Sciences, Inc. · R44 · FY2021 · AI
Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia
$999,997Atul Varadhachary · Fannin Partners, Llc · R44 · FY2025 · CA
Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative Colitis
$999,997Milton L Greenberg · Vivreon Biosciences, Llc · R44 · FY2025 · AI
Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative Colitis
$999,997Milton L Greenberg · Vivreon Biosciences, Llc · R44 · FY2024 · AI
Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia
$999,997Atul Varadhachary · Fannin Partners, Llc · R44 · FY2022 · CA
A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis
$999,989Neil A Fanger · Virtici, Llc · R44 · FY2025 · HL
Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening
$999,980Steven Joseph Darnell · Dnastar, Inc. · R44 · FY2020 · AI
Down Syndrome Connect Registry
$999,558Joaquin M. Espinosa · University Of Colorado Denver · OT2 · FY2025 · HD
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
$999,501Upendra Marathi · 7 Hills Pharma, Llc · R42 · FY2018 · CA
Coordinate Regulation of Virulence in Vibrio Cholerae
$999,436John J Mekalanos · Harvard Medical School · R37 · FY2025 · AI
Colorado AMC REACH Hub
$999,434Richard C Duke · University Of Colorado Denver · U01 · FY2019 · HL